Aurobindo Pharma’s step-down subsidiary -- Eugia Pharma Specialities has inaugurated the green-field manufacturing Unit located at Plot numbers 1 and 2, APIIC Industrial Park, Parawada, Phase III, Tadi Village, Parawada Mandal, Vishakhapatnam, Andhra Pradesh on October 16, 2023.
This Unit will manufacture general injectables and expected to supply globally in phases. The project cost of the Unit is around Rs 600 crore and the commercial production will be commenced during Q4 of FY24 in phases and subject to receipt of the necessary regulatory approvals from India as well as USA and the same will be disclosed in due course from time to time.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: